Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors[1][2][3][4][5][6][7].
Dose-dependently increased the proportion of apoptotic cells, with early apoptosis (Annexin V+/PI-) being the predominant type.
Displayed typical apoptotic features: nuclear shrinkage, chromatin condensation, nuclear fragmentation, and the formation of apoptotic bodies.
Increased the Caspase-3/8/9 cleavage products and PARP cleavage.
Increased the LC3-II/I ratio, upregulated Beclin-1 expression, and accelerated the degradation of p62.
Increased the expression of p-ASK1 and p-JNK, and decreased the expression of p-ERK.
Inhibited the protein expression of ECM proteins such as FN, Col-1, Col-3, and CTGF.
Specifically inhibited MMP13 rather than MMP10.
Inhibited Col-1, α-SMA, and CTGF.
Decreased the expression of type I collagen in a concentration-dependent manner.
Inhibited the gene expression of ECM proteins such as FN, Col-1, Col-3, and CTGF.
Significantly inhibited the mRNA expression of MMP10 (not obvious) and MMP13.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
Pulmonary fibrosis model induced by Bleomycin (HY-108345) established in adult male ICR mice (6-7 weeks)[2]
Dosage:
80 mg/kg
Administration:
Oral administration (p.o.), once daily for 28 days
Result:
Blocked BLM-induced histological changes of lung tissue.
Decreased the high levels of TGF-β1 and α-SMA.
Animal Model:
AMI model induced by underwent left anterior descending coronary artery (LAD) ligation established in male SPF C57/BL6 mice, aged 8-10 weeks and weighing 23-25 g[3]
Dosage:
0.5, 1.25, and 2.5 mg/kg
Administration:
Intramyocardial injection of the left ventricular myocardium, single dose
Result:
Significantly improved ejection fraction (EF%) and short-axis shortening rate (FS%).
Significantly reduced the area of myocardial infarction.
Reduced myocardial cell apoptosis and inflammatory cell infiltration.
Significantly reduced the expressions of HMGB1 and TLR4, as well as the phosphorylation of p-IkBα and p-P65, and the levels of inflammatory factors IL-1β, IL-6, and TNF-α.
Significantly enriched HMGB1/TLR4/NF-κB pathway.
Animal Model:
H460 cells induced xenograft tumor model established in male BALB-c nude mice (4-week-old)[4]
Dosage:
25 and 50 mg/kg
Administration:
Intraperitoneal injection (i.p.), for 21 days
Result:
Decreased the tumor weight and volume.
No significant biological toxicity.
Animal Model:
Renal fibrosis UUO model established in six-week-old C57BL/6 J mice[5]
Dosage:
80 mg/kg
Administration:
Oral administration (p.o.), once daily for 10 days
Result:
Ameliorated the obstructive kidney weight ratio.
Attenuated histological damage and collagen deposition in the kidneys.
Animal Model:
POF model established in SPF-grade female C57 mice, 6-8 weeks[6]
Dosage:
200 mg/mL with Specnuezhenide
Administration:
Oral administration (p.o.), once daily for 30 days
Result:
Increased the ovarian index and serum estradiol (E2) levels.
Reduced the level of follicle-stimulating hormone (FSH).
Extended the emotional cycle.
Increased the number and diameter of follicles.
Promoted ovarian angiogenesis (increase the expression of CD31 and VEGFA).
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (protect from light)。-80°C储存时，请在6个月内使用，-20°C储存时，请在1个月内使用。
可选溶剂
浓度溶剂体积质量
1 mg
5 mg
10 mg
25 mg
DMSO
1 mM
1.5752 mL
7.8760 mL
15.7520 mL
39.3800 mL
5 mM
0.3150 mL
1.5752 mL
3.1504 mL
7.8760 mL
10 mM
0.1575 mL
0.7876 mL
1.5752 mL
3.9380 mL
15 mM
0.1050 mL
0.5251 mL
1.0501 mL
2.6253 mL
20 mM
0.0788 mL
0.3938 mL
0.7876 mL
1.9690 mL
25 mM
0.0630 mL
0.3150 mL
0.6301 mL
1.5752 mL
30 mM
0.0525 mL
0.2625 mL
0.5251 mL
1.3127 mL
40 mM
0.0394 mL
0.1969 mL
0.3938 mL
0.9845 mL
50 mM
0.0315 mL
0.1575 mL
0.3150 mL
0.7876 mL
60 mM
0.0263 mL
0.1313 mL
0.2625 mL
0.6563 mL
80 mM
0.0197 mL
0.0984 mL
0.1969 mL
0.4922 mL
100 mM
0.0158 mL
0.0788 mL
0.1575 mL
0.3938 mL
Help & FAQs
Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.
Powered by Bioz
